People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action.
暂无分享,去创建一个
J. McGill | P. Groop | P. Rossing | K. Tuttle | H. Heerspink | D. Cherney | C. Matthieu
[1] T. Fleming,et al. Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation , 2022, Therapeutic innovation & regulatory science.
[2] P. Groop,et al. Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0-14 years: a population-based retrospective cohort study. , 2022, The lancet. Diabetes & endocrinology.
[3] B. Duncan,et al. IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 , 2021, Diabetes Research and Clinical Practice.
[4] G. Filippatos,et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.
[5] H. Heerspink,et al. The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes , 2019, Diabetes Care.
[6] A. Paterson,et al. Risk Factors for Kidney Disease in Type 1 Diabetes , 2019, Diabetes Care.
[7] A. Paterson,et al. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[8] D. Kohan,et al. Endothelin and Endothelin Antagonists in Chronic Kidney Disease , 2014, Kidney international.
[9] H. Parving,et al. Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate , 2004, Diabetologia.
[10] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.